ChemotherapyFDA-approvedFirst-line
Cisplatin
How it works
Damages the DNA of cancer cells, preventing them from reproducing. It also triggers an immune response against cancer cells.
Cancer types
Ovarian Cancer— All patients
Efficacy
Cisplatin has been shown to improve survival in ovarian cancer patients, with a median overall survival of approximately 30 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Diosmetin Enhances Effectiveness of Cancer Treatment in Lab Experiments | Ovarian Cancer | lab-study | — | Source → |
| Researchers Identify New Player in Lung Cancer Resistance | Lung Cancer | lab-study | — | Source → |
| Cancer Research Uncovers New Pathway for Cisplatin Resistance | Lung Cancer | lab-study | — | Source → |
| MicroRNA Linked to Breast Cancer Resistance to Chemotherapy | Breast Cancer | lab-study | — | Source → |
| Cisplatin May Weaken Cancer Treatment by Boosting Immune Suppression | Ovarian Cancer | lab-study | — | Source → |
| Understanding Cisplatin Resistance in Small Cell Lung Cancer | Lung Cancer | review | — | Source → |
| Testing Cisplatin and Radiation Therapy in Advanced Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Researchers Identify New Target to Overcome Cisplatin Resistance in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Geniposide Enhances Cisplatin Sensitivity in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Link between gene modification and chemotherapy resistance in ovarian cancer | Ovarian Cancer | lab-study | — | Source → |
| Ovarian Cancer Cells May Resist Treatment by Producing a Specific DNA Fragment | Ovarian Cancer | lab-study | Cisplatin showed limited efficacy in reducing tumor growth in resistant tumors. | Source → |
| Neutrophil Traps Contribute to Ovarian Cancer Resistance to Platinum | Ovarian Cancer | lab-study | — | Source → |
| Combining Cisplatin and Sulforaphane May Improve Lung Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| Tripterygium Glycosides May Help Overcome Chemotherapy Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Gene Linked to Ovarian Cancer Resistance to Chemotherapy | Ovarian Cancer | lab-study | The diagnostic potential of was moderate, with an area under the curve (AUC) of 0.792. | Source → |
| Researchers Investigate Role of HMGB1 in Overcoming Cisplatin Resistance | Ovarian Cancer | lab-study | — | Source → |
| New Compounds Show Promise in Fighting Lung Cancer | Lung Cancer | lab-study | The benzoxazole derivatives 1a and 1b exhibited anticancer activity against A549 cells, with half-maximal inhibitory concentration (IC) values of 17.41±0.16 and 20.50±0.08 µM, respectively. | Source → |
| Macrophage Exosomes Contribute to Lung Cancer Resistance to Cisplatin | Lung Cancer | lab-study | — | Source → |
| ULK2 may help ovarian cancer patients respond better to chemotherapy | Ovarian Cancer | lab-study | — | Source → |
| Cancer Cells May Resist Treatment with Help from Surrounding Cells | Lung Cancer | lab-study | — | Source → |
| New Tool Helps Cancer Cells Absorb Chemotherapy | Ovarian Cancer | lab-study | In vivo, DR-A2 significantly boosted the antitumor efficacy of cisplatin. | Source → |
| Fruit Extract from Sausage Tree Shows Anticancer Activity in Lab Experiments | Colorectal Cancer | lab-study | — | Source → |
| Evodiamine May Help Overcome Lung Cancer Resistance to Cisplatin | Lung Cancer | lab-study | The IC-50 for A549 cells was 4 µM, and for A549 cisplatin-resistant cells, it was 2 µM. | Source → |
| New Lung Cancer Treatment Combination Shows Promise | Lung Cancer | phase-2 | The 2-year survival rate was 88.1%, with a 3-year survival rate of 82.9%. | Source → |
| PD-L1 Upregulation Linked to Poor Prognosis in Ovarian Cancer | Ovarian Cancer | observational | — | Source → |
| Guiqi Yiyuan Ointment May Improve Cancer Treatment | Lung Cancer | animal-study | — | Source → |
| Cancer Cells Develop Resistance to Cisplatin | Lung Cancer | lab-study | Targeting FA metabolism with CPT1A inhibitors or CD36 antagonists, or blocking PARP activity, significantly reversed SART3-mediated resistance. | Source → |
| Wenxia Formula Extract May Help Overcome Lung Cancer Resistance to Cisplatin | Lung Cancer | animal-study | — | Source → |
| Hydrogels May Not Improve Cisplatin's Effectiveness in Breast Cancer | Breast Cancer | meta-analysis | — | Source → |
| Researchers Explore New Use for Old Cancer Therapy | Ovarian Cancer | lab-study | — | Source → |
| Combining Traditional Chinese Medicine with Cisplatin May Help Overcome Ovarian Cancer Resistance | Ovarian Cancer | lab-study | — | Source → |
| GJB2 protein linked to ovarian cancer resistance to chemotherapy | Ovarian Cancer | lab-study | — | Source → |
| HO-1 Depletion May Help Overcome Cisplatin Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Desensitizing Patients to Cisplatin for Ovarian Cancer Treatment | Ovarian Cancer | observational | — | Source → |
| ELK3's Role in Ovarian Cancer Resistance to Cisplatin | Ovarian Cancer | lab-study | — | Source → |
| Combining Cisplatin with GSK2606414 May Help Overcome Ovarian Cancer Resistance | Ovarian Cancer | lab-study | — | Source → |
| Anatolian Propolis May Help Fight Ovarian Cancer | Ovarian Cancer | lab-study | The IC value of propolis was determined as 0.342 ± 0.180 mg/mL in the A2780 cell line. | Source → |
| New Compound May Help Overcome Lung Cancer Resistance to Cisplatin | Lung Cancer | lab-study | — | Source → |
| Combining Chemotherapy Drugs Boosts Immune Response in Cancer | Colorectal Cancer | lab-study | — | Source → |
| Combining Temozolomide and Cisplatin in Colorectal Cancer Treatment | Colorectal Cancer | lab-study | — | Source → |
| MMP3's Role in Ovarian Cancer Resistance to Cisplatin | Ovarian Cancer | lab-study | siRNA-mediated MMP3 knockdown significantly reduced viability, proliferation, and invasion, and these effects were further enhanced when combined with cisplatin treatment. | Source → |
| KDM4A Gene Silencing May Help Overcome Chemotherapy Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Gene Linked to Chemotherapy Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Combining Oleanolic Acid and Cisplatin to Treat Pancreatic Cancer | Pancreatic Cancer | lab-study | The output of analysis of the anti-proliferative and cytotoxicity effect of OA and CIS tends to show the significant inhibition of cells in a dose-dependent manner with IC value of 5.75 μM OA and 2.95 μM of CIS. | Source → |
| New Insight into Ovarian Cancer Resistance to Treatment | Ovarian Cancer | lab-study | — | Source → |
| Combining Quercetin and Cisplatin May Improve Ovarian Cancer Treatment | Ovarian Cancer | lab-study | — | Source → |
| PARP Inhibitors May Help Lung Cancer Patients Respond Better to Chemotherapy | Lung Cancer | lab-study | — | Source → |
| Lung Cancer Cells May Adapt to Chemotherapy | Lung Cancer | lab-study | — | Source → |
| Combining silica nanoparticles, cisplatin, and quercetin may help treat ovarian cancer | Ovarian Cancer | animal-study | — | Source → |
| Ovarian Cancer Cells' Response to Cisplatin May Be Influenced by AUF1 Protein | Ovarian Cancer | lab-study | — | Source → |
| Combining aripiprazole with cisplatin may help treat pancreatic cancer | Pancreatic Cancer | lab-study | — | Source → |
| Propofol May Enhance Effectiveness of Ovarian Cancer Treatments | Ovarian Cancer | lab-study | — | Source → |
| New Study Compares Treatments for Rare Ovarian Tumors | Ovarian Cancer | phase-2 | Median progression-free survival was 27.7 months for paclitaxel and carboplatin, and 19.7 months for bleomycin, etoposide, and cisplatin. | Source → |
| Ovarian Cancer Biomarker Identified in Lab Study | Ovarian Cancer | lab-study | — | Source → |
| Cancer Research: METTL3 and circ_0000620's Role in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Combining Metformin with Cisplatin May Reduce Effectiveness in Ovarian Cancer Treatment | Ovarian Cancer | lab-study | — | Source → |
| Link between MUL1 gene and ovarian cancer resistance to cisplatin identified | Ovarian Cancer | lab-study | Platinum resistance increased with the upregulation of MUL1 expression (Cor = 0.5154, P = 0.02). | Source → |
| New Targets for Overcoming Cisplatin Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Gene Study Identifies New Targets for Ovarian Cancer Treatment | Ovarian Cancer | lab-study | — | Source → |
| Low-dose dihydroartemisinin may improve lung cancer treatment | Lung Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.